Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Mesenteric adipose tissue: from protective gatekeeper to driver of inflammatory bowel disease

Gliniak CM.

Narrative Review on Chronic Inflammation, Immune Modulation, Autoimmune Research, published in Immunometabolism (Cobham) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Immunometabolism (Cobham) (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42147738
PMCID
PMC13174941
DOI
10.1097/in9.0000000000000081

Abstract (original English)

Inflammatory bowel disease (IBD) defines a group of diseases, including Crohn's disease and ulcerative colitis, characterized by chronic inflammation of the gastrointestinal tract. Evidence suggests that visceral adipose tissue, particularly its mesenteric component, influences the course of IBD through its immunomodulatory properties. Mesenteric adipose tissue (MAT) is composed of multiple cell types, including adipocytes, preadipocytes, and immune cells, that collectively regulate energy balance and endocrine signaling. MAT is a unique fat depot as it directly connects along most of the intestinal serosa and harbors the arteries, veins, and lymph nodes that support intestinal function. MAT's placement at the intestinal barrier serves to contain microbial translocation and support the repair of intestinal epithelium. However, inflammation initiated by obesity or IBD renders it maladaptive, triggering an influx of immune cells that, in turn, release proinflammatory adipokines, cytokines, and chemokines, resulting in local and systemic metabolic effects. Clinical data strongly link the accumulation of inflammatory MAT in the pathology of Crohn's disease through the development of "creeping fat", a fibrotic, immune-rich tissue that shields the inflamed bowel but can also exacerbate the condition. The inflammatory mediators produced by MAT and the mechanisms by which they aggravat

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research